Editorial Board About Us

Allan J Pantuck

All articles from this author are listed below.

Volume 4, Number 3 Review Articles

Laparoscopic and Percutaneous Ablative Techniques in the Treatment of Renal Cell Carcinoma

Treatment Update

Arie S Belldegrun Allan J Pantuck Amnon Zisman Nicolette Janzen Kent Perry Peter Schulam

Renal cell carcinoma Radiofrequency ablation Cryoablation High-intensity

Volume 5, Number 3 Meeting Reviews

Best of the 2003 AUA Annual Meeting

Highlights from the 2003 Annual Meeting of the American Urological Association, April 26-May 1, 2003

Mesut Remzi Arie S Belldegrun Allan J Pantuck Michael Dobrovits Matthew B Gretzer Kazumasa Torimoto Randall B Meacham Ellen Shapiro Alan W Partin Michael B Chancellor J Curtis Nickel Jacob Rajfer Claus G Roehrborn Michael K Brawer Dean G Assimos Bob Djavan

Prostate cancer Renal cell carcinoma Benign prostatic hyperplasia Depression Bladder cancer Lower urinary tract symptoms Urinary tract infection Prostate-specific antigen Nephrolithiasis Overactive bladder Radical prostatectomy Peyronie’s disease Gleason score Transrectal ultrasound Erectile dysfunction Chronic prostatitis/chronic pelvic pain syndrome Acute urinary retention International Prostate Symptom Score Bacille Calmette-Guérin therapy Chronic Prostatitis Symptom Index MTOPS trial PLESS study Prostate tumor markers SELDI-TOF

Volume 5, Number 1 Meeting Reviews

Highlights from the 2nd Annual Winter Meeting of the Society of Urologic Oncology, December 1-2, 2001, Bethesda, MD

Urologic Oncology: Extraordinary Opportunities for Discovery

Allan J Pantuck Arie S Belldegrun Amnon Zisman

Kidney cancer Transitional cell carcinoma Society of Urologic Oncology Nephrectomy, radical

Volume 9, Number 2 Review Articles

Understanding the Natural Biology of Kidney Cancer: Implications for Targeted Cancer Therapy

Treatment Update

Allan J Pantuck Tobias Klatte Mark D Kleid Arie S Belldegrun

During the past several decades, there has been a significant increase in the understanding of the biology, clinical behavior, and prognostic factors of renal cell carcinoma (RCC). Such progress has led to greater sophistication in the diagnosis and classification of RCC. Here, we review recent advances in our knowledge of the biologic characteristics of RCC that have resulted in notable achievements in staging, prognosis, patient selection, and treatment. [Rev Urol. 2007;9(2):47-56]

Angiogenesis Genetics Molecular markers Targeted treatment Tumor-node-metastasis classification

Volume 14, Number 3 Review Articles

Systemic Therapy for Metastatic Renal Cell Carcinoma: A Review and Update

Management Update

Allan J Pantuck Karim Chamie Joshua E Logan Edward N Rampersaud Geoffrey A Sonn Dennis J Slamon Fairooz F Kabbinavar Arie S Belldegrun

An in-depth understanding of metastatic renal cell carcinoma (mRCC) is important so that practitioners can make informed evidenced-based decisions with patients to optimize not only quantity of life but quality of life as well. Therefore, this review focuses on the biology of mRCC as it relates to targets for therapy, as well as on the small molecules rationally designed with these targets in mind. In addition, anticipated emerging therapies are highlighted, including the new tyrosine kinase inhibitors axitinib and tivozanib, as well as new immune-based therapies such as dendritic cell-based vaccines and antibodies. We also briefly review recent reports from the emerging field of predicting drug response based on molecular markers. And finally, management of metastatic non-clear cell RCC histologies are discussed focusing on available evidence to direct decision making when assessing therapeutic options. [Rev Urol. 2012;14(3/4):65-78 doi: 10.3909/riu0562] © 2013 MedReviews®, LLC

Metastatic renal cell carcinoma Tyrosine kinase inhibitors Dendritic cell-based vaccines